The World Health Organisation (WHO) has granted approval to Bharat Biotech’s Covaxin for Emergency Use Listing (EUL) on Wednesday.
WHO’s Technical Advisory Group met on Wednesday to take a final decision and based on the effectiveness of Covaxin requested by the World Health Organization, emergency use of Covaxin is now recognized.
Covaxin can now be said to be a step towards the formal recognition of WHO. WHO said that the Indian Biotech vaccine could be used for people who are 18 years of age and older.
Covexin is manufactured by Hyderabad-based Bharat Biotech and Indian Council of Medical Research and is one of the six vaccines that have received emergency use authorisation from India’s drug regulator.
Meanwhile, Bharat Biotech on Wednesday said that the Central Drugs Standard Control Organisation (CDSCO) has approved the extension of shelf life of Covaxin up to 12 months from the date of manufacture.
“The CDSCO has approved the extension of shelf life of Covaxin up to 12 months, from the date of manufacture. This approval of shelf life extension is based on the availability of additional stability data, which was submitted to CDSCO,” Bharat Biotech said in a tweet.
